Discover
PSTV
Plus Therapeutics, Inc.
3.85
1 x 3.00
1 x 4.96
bid
ask
-
0.31
7.45%
01:16 PM
timesize
| Ytd | -69.80% | |
| 1y | -50.32% |
3.84
day range
4.20
2.90
52 week range
23.50
| Open | 4.15 | Prev Close | 4.16 | Low | 3.84 | High | 4.20 | Mkt Cap | 26.50M |
| Vol | 188.56K | Avg Vol | 305.18K | EPS | 21.56 | P/E | 0.18 | Forward P/E | -0.52 |
| Beta | 0.69 | Short Ratio | 0.98 | Inst. Own | 11.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-04 | 50-d Avg | 5.61 | 200-d Avg | 9.60 | 1yr Est | 15.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.46 | -0.46 | N/A | N/A |
| 2024-08-14 | 2024-06 | 0 | -0.71 | N/A | N/A |
| 2024-05-15 | 2024-03 | 0 | -0.75 | N/A | N/A |
| 2024-03-05 | 2023-12 | -0.78 | -0.7 | 0.08 | 10.26% |
| 2023-10-31 | 2023-09 | -0.58 | -1 | -0.42 | -72.41% |
| 2023-08-14 | 2023-06 | -1.91 | -0.59 | 1.32 | 69.11% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-12-09 | Ascendiant Capital | Upgrade | Buy | Buy |
| 2024-11-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-11-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-08-15 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-09-10 | CLOWES HOWARD | Director | 26.50K | Purchase |
| 2024-09-12 | HAWKINS RICHARD JAMES | Director | 0.00 | Purchase |
| 2024-09-09 | HEDRICK MARC HAMILTON | Chief Executive Officer | 20.43K | Purchase |
| 2024-05-07 | LENK ROBERT P | Director | 29.33K | Purchase |
| 2024-09-10 | PETERSEN GREG B | Director | 48.92K | Purchase |
| 2024-09-09 | SIMS ANDREW JOHN HUGH MACINTYRE | Chief Financial Officer | 9.82K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | AIGH Capital Management LLC | 560.91K | 600.17K | 9.51% |
| 2024-09-29 | Geode Capital Management, LLC | 54.27K | 58.07K | 0.92% |
| 2024-09-29 | Vanguard Group Inc | 32.54K | 34.82K | 0.55% |
| 2024-09-29 | Ashton Thomas Private Wealth, LLC | 12.91K | 13.82K | 0.22% |
| 2024-09-29 | Blackrock Inc. | 6.96K | 7.45K | 0.12% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 3.71K | 3.97K | 0.06% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 35.47K | 37.95K | 0.60% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 32.54K | 34.82K | 0.55% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 8.90K | 9.52K | 0.15% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 8.28K | 8.86K | 0.14% |
| 2024-10-30 | Fidelity Total Market Index Fund | 5.32K | 5.69K | 0.09% |
Split
| Split | Date |
|---|---|
| 1 : 25 | 2026-04-02 |
| 1 : 15 | 2023-05-01 |
| 1 : 50 | 2019-08-06 |
| 1 : 10 | 2018-05-24 |
| 1 : 15 | 2016-05-12 |